LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
Abstract The refractory of castration-resistant prostate cancer (CRPC) is mainly reflected in drug resistance. The current research on the resistance mechanism of CRPC is still in its infancy. In this study, we revealed for the first time the key role of LncRNA PCBP1-AS1 in CRPC drug resistance. Thr...
Main Authors: | Boya Zhang, Mingpeng Zhang, Chunyi Shen, Guancong Liu, Fan Zhang, Jingyu Hou, Weitao Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-04144-2 |
Similar Items
-
lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway
by: Luo T, et al.
Published: (2020-07-01) -
Target LncRNA CYTOR reverse enzalutamide resistance in castration resistant prostate cancer through regulating alternative splicing of AR-V7
by: Z. Shang, et al.
Published: (2020-07-01) -
Using lncRNA Sequencing to Reveal a Putative lncRNA-mRNA Correlation Network and the Potential Role of PCBP1-AS1 in the Pathogenesis of Cervical Cancer
by: Linhan Li, et al.
Published: (2021-03-01) -
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
by: Yundong He, et al.
Published: (2021-03-01) -
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
by: Qiuhui Li, et al.
Published: (2018-09-01)